secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2023-06-29T23:59:59+00:00
Accession:  0001157523-23-001047
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra reports positive Phase 2 data for ADX-2191 in retinitis pigmentosa
--------------------------------------------------------------------------

- Statistically significant improvement in best corrected visual acuity (P<0.0001) and low-light visual acuity (P=0.0001).
- Perimetry showed improved macular sensitivity (P<0.0001) and dark-adapted peripheral sensitivity (P<0.0001).
- Electroretinography time to response improved (P=0.02); no safety concerns identified.
- All 8 patients completed trial; ADX-2191 well tolerated with no serious adverse events.
- Company plans to discuss Phase 2/3 trial design with regulatory authorities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323001047/0001157523-23-001047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323001047/a53436990.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer